IP Library Granted Patent US 8,614,101
Granted Patent B2
US 8,614,101 · App. 12/502,662 · Granted Dec 24, 2013

In situ lysis of cells in lateral flow immunoassays

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,614,101
App. No.
12/502,662
Granted
Dec 24, 2013
Kind
B2
Abstract

Devices and methods incorporate lysis agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters a lysis agent. The lysis agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the initially lysis agent is localized between the sample application zone and the conjugate zone. The lysis agent is preferably soluble or miscible in the sample transport liquid, and the lysis agent is solubilized and activated upon contact with the sample transport liquid. The sample transport liquid then contains both lysis agent in solution or suspension and sample components in suspension. Any lysis-susceptible components in a sample, then being exposed in suspension to the lysis agent, are themselves lysed in situ. The running buffer then carries the analyte, including any lysis-freed components, to the detection zone.

Claims (30)

1. A method for detecting at least one target in a sample, comprising the steps of:

a) transferring a sample that is not lysed onto a sample application zone of a sample analysis device;

b) applying an elution medium comprising at least one first lysis agent to the sample analysis device to transfer the sample from the sample application zone to a detection zone, wherein the sample encounters the at least one first lysis agent in the elution medium such that the sample is lysed prior to reaching the detection zone; and

c) analyzing the sample for a presence of the target in the sample, comprising the substep of detecting a presence of the target in the sample by detecting a signal from the labeled binding partner in the detection zone;

wherein the sample application zone, and the detection zone are on a chromatographic test strip, and the chromatographic test strip further comprises a conjugate zone, wherein the conjugate zone comprises at least one labeled binding partner that is able to migrate with the elution medium and wherein the labeled binding partner encounters the sample while the sample is being transferred from the sample application zone to the detection zone and binds to the target when the target is present in the sample;

wherein the chromatographic test strip further comprises a lysis zone that comprises at least one second lysis agent, wherein the lysis zone is located on the chromatographic test strip in a location selected from the group consisting of:

i) between the sample application zone and the conjugate zone;

ii) a location where at least a portion of the lysis zone overlaps the sample application zone;

iii) a location where at least a portion of the lysis zone overlaps the conjugate zone; and

iv) a location where at least a portion of the lysis zone overlaps the sample application zone and at least a portion of the lysis zone overlaps the conjugate zone.

2. The method of claim 1 , further comprising the step of:

d) determining at least one result of an analysis performed in step (c) within 20 minutes of transferring the sample in step (a).

3. The method of claim 2 , wherein the result is determined within 10 minutes of transferring the sample in step (a).

4. The method of claim 2 , wherein the result is determined within one to five minutes of applying the elution medium in step (b).

5. The method of claim 1 , wherein the target is a target selected from the group consisting of pathogens and/or allergy-associated components; and wherein the sample is from a body fluid.

6. The method of claim 1 , wherein the conjugate zone is located between the sample application zone and the detection zone.

7. The method of claim 1 , wherein the chromatographic test strip further comprises a blocking zone comprising a barrier that slows or arrests lysed materials effectively larger than a porosity of the barrier.

8. The method of claim 7 , wherein the barrier is selected from the group consisting of a physical barrier or a biological barrier.

9. The method of claim 7 , wherein the blocking zone is located in a location on the chromatographic test strip selected from the group consisting of:

a) between the sample application zone and the conjugate zone;

b) between the conjugate zone and the detection zone; and

c) between the sample application zone and the detection zone.

10. The method of claim 1 , wherein the first lysis agent and the second lysis agent are selected from the group consisting of:

a) at least one salt;

b) at least one amphoteric agent;

c) at least one ionic detergent;

d) at least one non-ionic detergent;

e) at least one enzyme;

f) urea; and

g) any combination of a) through f).

Assignments (4)
SECURITY INTEREST Recorded Dec 20, 2018
From: RAPID PATHOGEN SCREENING, INC.; RPS DIAGNOSTICS, INC.
To: LUMOS DIAGNOSTICS HOLDINGS PTY LTD
Reel/Frame 047834/0030 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2018
From: ROS ACQUISITION OFFSHORE LP
To: RAPID PATHOGEN SCREENING, INC.
Reel/Frame 047834/0367 →
SECURITY INTEREST Recorded Oct 10, 2014
From: RAPID PATHOGEN SCREENING, INC.
To: ROS ACQUISITION OFFSHORE LP
Reel/Frame 033929/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2009
From: VANDINE, ROBERT W.; BABU, UMA MAHESH; SAMBURSKY, ROBERT P.
To: RAPID PATHOGEN SCREENING, INC.
Reel/Frame 022958/0303 →